Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intratumoral G100 in Follicular Lymphoma
NCT02501473Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Feb 2016
- Primary completion
- Aug 2019
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of G100 in follicular lymphoma (FL), sponsored by Merck & Co.. Started Feb 2016; status: terminated.
02
Drugs
G100
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT02501473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02501473.